Prelude reports Phase 1 interim data: PRT3789 shows 3 confirmed PRs in NSCLC/esophageal, well tolerated

Prelude Therapeutics Inc

3 confirmed partial responses in 2 esophageal and 1 NSCLC patient out of 26 evaluable; 7 patients had tumor shrinkage.
PRT3789 was well tolerated in 65 patients; no dose-limiting toxicities or drug-related serious adverse events.
Dose escalation continues to cohort 9 (500 mg once weekly); MTD not yet reached.
Company expects to confirm biologically active dose as monotherapy by year-end.
Data presented at ESMO 2024; also selected for plenary session at EORTC-NCI-AACR Symposium in October 2024.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.